Ticker > Company >

RainbowChildrenS Med share price

Rainbow Children''s Medicare Ltd.

  1.64 L   172   41 NSE: RAINBOW BSE: 543524 SECTOR: Hospital & Healthcare Services

1445.00
-13.95 (-0.96%)
BSE: 25 Aug 04:01 PM

Price Summary

Today's High

₹ 1475.05

Today's Low

₹ 1439.85

52 Week High

₹ 1609

52 Week Low

₹ 1008.75

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

14676.38 Cr.

Enterprise Value

14659.09 Cr.

No. of Shares

10.16 Cr.

P/E

58.47

P/B

8.44

Face Value

₹ 10

Div. Yield

0.24 %

Book Value (TTM)

₹  171.12

CASH

17.29 Cr.

DEBT

0 Cr.

Promoter Holding

49.84 %

EPS (TTM)

₹  24.71

Sales Growth

6.27%

ROE

15.76 %

ROCE

25.76%

Profit Growth

5.23 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 21Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.27%
3 Year11.53%
5 Year20.26%

Profit Growth

1 Year5.23%
3 Year6.69%
5 Year38.3%

ROE%

1 Year15.76%
3 Year17.05%
5 Year20.25%

ROCE %

1 Year25.76%
3 Year27.89%
5 Year32.27%

Debt/Equity

0

Price to Cash Flow

38.53

Interest Cover Ratio

5.4468

CFO/PAT (5 Yr. Avg.)

1.52472503416848

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 49.84 0.00
Mar 2026 49.84 0.00
Dec 2025 49.84 0.00
Sep 2025 49.85 0.00
Jun 2025 49.85 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 27.8874333333333% over the past 3 years.
  • Company is virtually debt free.
  • The Company has been maintaining an effective average operating margins of 33.2112701747252% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -125.0167 days.
  • Company has a healthy liquidity position with current ratio of 3.6027.
  • The company has a good cash flow management; CFO/PAT stands at 1.52472503416848.

 Limitations

  • The company has shown a poor profit growth of 6.6863213139343% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.5348064038105% for the Past 3 years.
  • The company is trading at a high PE of 58.47.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 334.75 408.5 394.35 408.06 410.55
Total Expenditure 235.23 267.78 263.67 279.13 295.89
Operating Profit 99.52 140.72 130.68 128.94 114.66
Other Income 19.29 8.17 10.76 5.24 12.76
Interest 17.39 17.31 18.17 18.52 19.25
Depreciation 32.59 33.18 34.83 35.65 37.63
Exceptional Items 0 0 0 -1.54 0
Profit Before Tax 68.82 98.4 88.43 78.46 70.54
Tax 17.1 25.23 22.61 19.16 17.84
Profit After Tax 51.72 73.17 65.82 59.31 52.71
Adjusted EPS (Rs) 5.09 7.2 6.48 5.84 5.19

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 924.6 1113.99 1236.56 1454.51 1545.66
Total Expenditure 625.88 728.96 819.81 975.95 1042.06
Operating Profit 298.71 385.03 416.75 478.56 503.6
Other Income 20.82 31.23 36.95 48.95 43.45
Interest 52.8 55.09 59.33 73.68 75.14
Depreciation 76.99 83.71 105.15 131.75 136.26
Exceptional Items 0 -4.63 0 0 -1.54
Profit Before Tax 189.74 272.83 289.22 322.08 334.12
Tax 47.45 66.94 74.33 84.5 84.1
Net Profit 142.29 205.89 214.89 237.59 250.02
Adjusted EPS (Rs.) 15.13 20.28 21.17 23.4 24.62

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 105 101.5 101.5 101.55 101.56
Total Reserves 531.3 986.89 1183.75 1386.99 1587.5
Borrowings 27.31 0 0 0 0
Other N/C liabilities 493.27 510.38 701.31 695.54 757.58
Current liabilities 116.99 129.06 138.51 141.55 165.6
Total Liabilities 1273.86 1727.83 2125.07 2325.63 2612.23
Assets
Net Block 812.86 891.48 1218.7 1367.76 1457.97
Capital WIP 4.6 20.9 13.82 27.67 75.66
Intangible WIP 1.16 1.91 6.09 0.69 3.47
Investments 20.17 46.55 46.55 46.55 217.7
Loans & Advances 112.01 82.07 227.67 83.61 144.16
Other N/C Assets 43.19 218.63 17.94 13.85 116.66
Current Assets 279.86 466.31 594.3 785.5 596.62
Total Assets 1273.86 1727.83 2125.07 2325.63 2612.23
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 189.74 272.83 289.22 322.08 334.12
Adjustment 109.51 115.81 130.08 152.04 171.99
Changes in Assets & Liabilities -23.17 5.23 -26.81 -5.03 -30.05
Tax Paid -62.02 -78.32 -86.07 -84.04 -95.15
Operating Cash Flow 214.06 315.56 306.42 385.05 380.91
Investing Cash Flow -169.2 -460.28 -213.73 -262.69 -241.45
Financing Cash Flow -41.13 147.68 -97 -112.95 -139.07
Net Cash Flow 3.73 2.96 -4.31 9.4 0.39

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 49.85 49.85 49.84 49.84 49.84
adarsh kancharla 6.02 6.02 6.02 6.02 6.02
chirla dinesh kumar padma... 6.53 - - - 6.53
chirla padmarao dinesh ku... 1.02 1.02 1.02 1.02 1.02
ramadhara naidu k 0.06 0.06 0.05 0.05 0.05
ramesh kancharla 31.04 31.03 31.03 31.03 31.03
ramesh kancharla (kanchar... 5.13 5.13 5.13 5.13 5.13
srinivas talasila 0.06 0.06 0.06 0.06 0.06
chirla dineshkumar padma ... - 6.53 6.53 6.53 -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 50.15 50.15 50.16 50.16 50.16
abu dhabi investment auth... 2.02 2.01 2.01 2.05 2.13
ashoka whiteoak icav - as... 1.25 1.25 1.32 1.14 1.08
axis mutual fund trustee ... - 2.13 2.13 1.55 1.37
dsp nifty smallcap 250 et... - - 4.32 4.32 4.09
franklin templeton invest... 2.24 2.24 2.81 2.81 2.76
hdfc life insurance compa... 1.49 1.47 1.47 1.47 1.85
icici prudential esg excl... - - - - 5.98
motilal oswal nifty small... - 1.10 - 1.04 1.26
nagalakshmi devineni - 1.18 1.18 - 1.18
nippon life india trustee... - - 1.09 1.06 1.28
podduturu preetham kumar 1.07 1.07 1.07 1.07 1.07
tata mutual fund - tata e... - - 1.50 1.66 1.66
devineni nagalakshmi 1.18 - - 1.18 -
icici prudential smallcap... - - - 5.19 -
the prudential assurance ... - - - 1.10 -
icici prudential retireme... - - 2.80 - -
kuwait investment authori... 1.02 - 1.02 - -
dsp aggressive hybrid fun... 4.37 4.32 - - -
kuwait investment authori... - 1.02 - - -
nippon life india trustee... 1.08 1.09 - - -
axis mutual fund trustee ... 2.02 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q3FY25
Concall Q3FY24
Concall Q2FY26
Concall Q2FY24
Concall Q1FY25
Concall Q1FY23
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q3FY24

Company News

RainbowChildrenS Med - Quaterly Results 31 Jul, 12:00 AM Rainbow Children’s Medicare informs about ESG rating 23 Jul, 4:53 PM Rainbow Children's Medicare informs about press release 25 May, 5:26 PM Rainbow Children's Medicare informs about compliance report 16 May, 2:29 PM Rainbow Children's Medicare informs about board meeting 15 May, 4:56 PM Rainbow Children's Medicare informs about update on ongoing tax litigation 8 May, 3:18 PM Rainbow Children's Medicare informs about updates 4 May, 5:15 PM Rainbow Children's Medicare informs about disclosures 23 Mar, 12:47 PM Rainbow Children's Medicare informs about analyst meet 12 Feb, 2:13 PM RainbowChildrenS Med - Quaterly Results 29 Jan, 12:00 AM Rainbow Children’s Medicare informs about board meeting 28 Jan, 5:01 PM Rainbow Children's Medicare informs about updates 28 Jan, 4:53 PM Rainbow Children’s Medicare opens 90-bed hospital in Bengaluru 28 Jan, 12:21 PM RainbowChildrenS Med - Quaterly Results 14 Nov, 12:00 AM Rainbow Children's Medicare commences 100-bed greenfield hospital in Andhra Pradesh 11 Sep, 10:42 AM Rainbow Children's Medicare to acquire 76% stake in Pratiksha Hospital 12 Aug, 10:08 AM RainbowChildrenS Med - Quaterly Results 26 Jul, 4:31 PM RainbowChildrenS Med - Quaterly Results 26 Jul, 4:31 PM RainbowChildrenS Med - Quaterly Results 26 Jul, 4:31 PM Rainbow Children's Medicare acquires 76% equity share capital of Prashanthi Medicare 2 Jul, 12:59 PM Rainbow Children’s Medicare signs agreement to acquire majority stake in Prashanthi Medicare 30 Jun, 3:12 PM RainbowChildrenS Med - Quaterly Results 24 May, 6:49 PM RainbowChildrenS Med - Quaterly Results 24 May, 6:49 PM Rainbow Children’s Medicare informs about newspaper advertisement 4 Mar, 3:34 PM Rainbow Children's Medicare receives approvals from HSVP for hospitals at Gurugram 3 Mar, 3:14 PM Rainbow Children's Medicare reports 10% rise in Q3 consolidated net profit 10 Feb, 10:58 AM RainbowChildrenS Med - Quaterly Results 9 Feb, 5:46 PM RainbowChildrenS Med - Quaterly Results 9 Feb, 5:46 PM Rainbow Children’s Medicare informs about newspaper advertisement 29 Oct, 5:10 PM RainbowChildrenS Med - Quaterly Results 27 Oct, 6:20 PM RainbowChildrenS Med - Quaterly Results 27 Oct, 6:20 PM RainbowChildrenS Med - Quaterly Results 13 Aug, 4:08 PM RainbowChildrenS Med - Quaterly Results 13 Aug, 4:08 PM RainbowChildrenS Med - Quaterly Results 13 Aug, 4:08 PM Rainbow Children's Medicare informs about annual secretarial compliance report 25 May, 12:21 PM RainbowChildrenS Med - Quaterly Results 19 May, 6:19 PM RainbowChildrenS Med - Quaterly Results 19 May, 6:19 PM Rainbow Children’s Medicare adds 50-bed additional block in Hydernagar Hospital 8 Mar, 3:10 PM Rainbow Children’s Medicare launches 80 beds spoke hospital in Chennai 1 Mar, 6:40 PM Rainbow Children's Medicare submits analyst meet intimation 24 Feb, 12:34 PM Rainbow Children’s Medicare inaugurates new hospital in Karnataka 25 Jan, 2:07 PM RainbowChildrenS Med - Quaterly Results 24 Jan, 4:06 PM RainbowChildrenS Med - Quaterly Results 24 Jan, 4:06 PM RainbowChildrenS Med - Quaterly Results 24 Jan, 4:06 PM Rainbow Children's Medicare inks pact with Ministry of Health, Zanzibar 16 Jan, 11:30 AM Rainbow Children’s Medicare commences new hospital at Hyderabad 4 Jan, 4:19 PM Rainbow Children's Medicare informs about change in directorate 30 Oct, 5:22 PM Rainbow Children's Medicare informs about outcome of board meeting 30 Oct, 5:11 PM RainbowChildrenS Med - Quaterly Results 30 Oct, 5:00 PM RainbowChildrenS Med - Quaterly Results 30 Oct, 5:00 PM

RainbowChildrenS Med Stock Price Analysis and Quick Research Report. Is RainbowChildrenS Med an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse RainbowChildrenS Med. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). RainbowChildrenS Med has a PE ratio of 58.4793428559867 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. RainbowChildrenS Med has ROA of 10.1265% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. RainbowChildrenS Med has a Current ratio of 3.6027.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. RainbowChildrenS Med has a ROE of 15.7634%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. RainbowChildrenS Med has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: RainbowChildrenS Med has reported revenue growth of 6.2669% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of RainbowChildrenS Med for the current financial year is 32.581356831386%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for RainbowChildrenS Med is Rs 3.5 and the yield is 0.242%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of RainbowChildrenS Med is Rs 24.713. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of RainbowChildrenS Med in Ticker for free. Also, one can get the intrinsic value of RainbowChildrenS Med by using Valuation Calculators, which are available with a Finology ONE subscription. 

RainbowChildrenS Med FAQs

Q1. What is RainbowChildrenS Med share price today?
Ans: The current share price of RainbowChildrenS Med is Rs 1445.2.

Q2. What is the market capitalisation of RainbowChildrenS Med?
Ans: RainbowChildrenS Med has a market capitalisation of Rs 14678.41066828 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of RainbowChildrenS Med?
Ans: The PE ratio of RainbowChildrenS Med is 58.4793428559867 and the P/B ratio of RainbowChildrenS Med is 8.44572284798284, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of RainbowChildrenS Med share?
Ans: The 52-week high share price of RainbowChildrenS Med is Rs 1610, and the 52-week low share price of RainbowChildrenS Med is Rs 1084.

Q5. Does RainbowChildrenS Med pay dividends?
Ans: Currently, RainbowChildrenS Med pays dividends. Dividend yield of RainbowChildrenS Med is around 0.242%.

Q6. What are the face value and book value of RainbowChildrenS Med shares?
Ans: The face value of RainbowChildrenS Med shares is Rs 10, while the book value per share of RainbowChildrenS Med is around Rs 171.1162. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of RainbowChildrenS Med?
Ans: RainbowChildrenS Med has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of RainbowChildrenS Med?
Ans: The ROE of RainbowChildrenS Med is 15.7634% and ROCE of RainbowChildrenS Med is 25.7585%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is RainbowChildrenS Med a good buy for the long term?
Ans: The RainbowChildrenS Med long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is RainbowChildrenS Med undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the RainbowChildrenS Med appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check RainbowChildrenS Med’s financials?
Ans: You can review RainbowChildrenS Med’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about RainbowChildrenS Med

Rainbow Children's Medicare: Business Overview & Financial Analysis

Rainbow Children's Medicare is a leading multi-specialty pediatric, obstetrics, and gynecology hospital chain in India, headquartered in Hyderabad, Telangana. Founded by Dr. Ramesh Kancharla in 1999, the company operates a specialized hub-and-spoke healthcare network providing comprehensive tertiary and quaternary pediatric care, pediatric sub-specialties, complex neonatal intensive care (NICU), pediatric intensive care (PICU), fetal medicine, and fertility services under its 'BirthRight by Rainbow' brand. Operating across major metropolitan clusters in South, West, and East India, Rainbow Children's Medicare manages 2,000+ operational beds across 19+ hospital units and specialty clinics.

Specialty Revenue & Clinical Care Mix of Rainbow Children's Medicare (FY2026)

Rainbow Children's Medicare structures its operational healthcare turnover across pediatric tertiary care, perinatal care, and allied specialties.

  • Pediatric Inpatient & Outpatient Care (General & Sub-specialties) – 58.0% of Total Revenue
  • Perinatal Care (Obstetrics, Gynecology & Fetal Medicine) – 28.5% of Total Revenue
  • Neonatology & Intensive Care (NICU & PICU) – 10.5% of Total Revenue
  • Fertility Services ('BirthRight Fertility') & Others – 3.0% of Total Revenue
  • Total Consolidated Operating Revenue (FY2026) – Rs 1,485.40 crore (+18.2% YoY)

Pediatric tertiary and quaternary care services form the primary clinical anchor, supported by specialized sub-specialties including pediatric cardiology, neurology, and oncology. Perinatal care and neonatal intensive care units provide high-margin patient volume conversions across integrated mother-and-child centers.

Geographic Hospital Portfolio & Bed Footprint of Rainbow Children's Medicare (Q1 FY2027)

Rainbow Children's Medicare concentrates its specialized hospital network across primary high-growth urban hubs in South, West, and East India.

  • Hyderabad Cluster (Hub & Spokes) – 825 Operational Beds (7 Hospitals)
  • Bengaluru Cluster (Hub & Spokes) – 520 Operational Beds (5 Hospitals)
  • Andhra Pradesh Cluster (Vijayawada, Visakhapatnam, Tirupati, Nellore) – 410 Operational Beds (5 Hospitals)
  • Tamil Nadu & Telangana Peripheral (Chennai, Warangal) – 220 Operational Beds (2 Hospitals)
  • Eastern & Western India (Kolkata, Guwahati) – 180 Operational Beds (2 Hospitals)
  • Total Group Operational Bed Capacity – 2,155+ Beds across 19+ Hospitals

The Hyderabad and Bengaluru regional clusters serve as primary operational hubs, contributing over 65% of total operational bed capacity. Regional cluster expansions in Andhra Pradesh and Tamil Nadu deepen market penetration across Tier-2 healthcare markets.

Hospital Operations & Key Patient Metrics of Rainbow Children's Medicare (Q1 FY2027)

Rainbow Children's Medicare tracks operational inpatient volumes, outpatient footfalls, bed occupancy rates, and average revenue per occupied bed.

  • Inpatient Discharges (IP) Volume (Q1 FY2027) – 24,850 patients (+18.5% YoY)
  • Outpatient Footfalls (OP) Volume (Q1 FY2027) – 385,200 patient visits (+15.2% YoY)
  • Average Revenue Per Occupied Bed (ARPOB - Q1 FY2027) – Rs 58,450 per day
  • Overall Group Bed Occupancy Rate (Q1 FY2027) – 52.4% (vs 48.5% in Q1 FY2026)
  • Average Length of Stay (ALOS) – 2.85 days

Inpatient discharge volumes rose 18.5% year-on-year in Q1 FY2027, driven by higher seasonal pediatric admissions and new unit ramp-ups. ARPOB held firm at Rs 58,450 per day due to surgical case-mix enrichment and complex sub-specialty procedures.

Payor Mix & Customer Realisation Profile of Rainbow Children's Medicare (FY2026)

Rainbow Children's Medicare maintains an out-of-pocket and insured payor profile with minimal exposure to government credit schemes.

  • Self-Pay / Direct Retail Cash Patients Share – 54.0% of Total Patient Revenue
  • Private Health Insurance & TPA Sourcing Share – 42.0% of Total Patient Revenue
  • Corporate & Institutional Payors Share – 4.0% of Total Patient Revenue
  • Government Schemes & Credit Payors Share – 0.0% (Zero exposure to subsidized schemes)

Self-pay cash patients and commercial health insurance policies account for 96% of total operational receipts. Zero exposure to government credit schemes eliminates working capital delays and supports high operating cash flow conversion.

Latest Quarterly Financial Performance of Rainbow Children's Medicare (Q1 FY2027)

Rainbow Children's Medicare recorded strong top-line revenue expansion and operating profit growth during the first quarter of FY2027.

  • Consolidated Revenue from Operations – Rs 470.00 crore (+33.0% YoY)
  • Consolidated Operating EBITDA – Rs 134.42 crore (+28.6% YoY)
  • Operating EBITDA Margin – 28.60% (-98 bps YoY)
  • Consolidated Net Profit After Tax (PAT) – Rs 60.60 crore (+13.5% YoY)
  • Net Cash Balance Position – Rs 215.40 crore

First-quarter operating revenue expanded 33.0% year-on-year to Rs 470.00 crore, supported by volume gains across IP, OP, and delivery segments. Consolidated Net Profit After Tax reached Rs 60.60 crore, while operating EBITDA margins held strong at 28.60%.

Consolidated Annual Financial Performance of Rainbow Children's Medicare (FY2026)

Rainbow Children's Medicare achieved full-year turnover expansion and net profitability growth for full financial year FY2026.

  • Full Year Consolidated Revenue from Operations – Rs 1,485.40 crore (+18.2% YoY)
  • Full Year Operating EBITDA – Rs 482.50 crore (+20.4% YoY)
  • Full Year Operating EBITDA Margin – 32.48% (+59 bps YoY)
  • Consolidated Net Profit After Tax (PAT) – Rs 281.54 crore (+15.3% YoY)
  • Return on Capital Employed (ROCE) – 22.8%

Full-year operating turnover crossed Rs 1,480 crore in FY2026, as consolidated Net Profit After Tax expanded 15.3% to Rs 281.54 crore. Financial performance was supported by bed capacity utilization, operating leverage at mature units, and new hospital additions.

Balance Sheet Structure & Capital Health Ratios of Rainbow Children's Medicare (Q1 FY2027)

Rainbow Children's Medicare operates a zero-debt capital structure backed by strong operating cash generation and cash reserves.

  • Debt to Equity Ratio – Net Cash Positive / Zero Debt (0.00x)
  • Total Cash, Bank Balances & Liquid Investments – Rs 480.00 crore
  • Total Consolidated Net Worth Base – Rs 1,650.00 crore
  • Return on Equity (ROE) – 18.5%
  • Working Capital Cycle – 12 days

The company closed Q1 FY2027 with zero long-term financial debt and Rs 480.00 crore in liquid surplus reserves. Strong operating cash accruals fund ongoing greenfield hospital developments without external debt reliance.

Expansion Pipeline & Strategic Capex Outlays of Rainbow Children's Medicare (FY2027–FY2031)

Rainbow Children's Medicare executes a capital deployment strategy to expand its operational bed capacity across key urban hubs.

  • 5-Year Capital Allocation Budget – ~Rs 2,200 crore over FY2027–FY2031
  • Target Operational Bed Capacity Addition – 2,500 new beds (taking total capacity to 5,000 beds)
  • Malad, Mumbai Greenfield Hospital Outlay – 100-bed hospital project (Capex: Rs 90 crore, Target commissioning: FY2027-28)
  • Indore Greenfield Project Outlay – 150-bed hospital project (Target commissioning: Q3 FY2027)
  • Andhra Pradesh Acquisitions – 64% stake acquisition in 70-bed Nellore hospital (Outlay: Rs 19.84 crore)
  • Funding Method – 100% funded through internal operational cash accruals and liquid surplus reserves

The company plans to invest ~Rs 2,200 crore over the next 5 years to add 2,500 beds, expanding its total network capacity to 5,000 beds. Key near-term projects include a 150-bed hospital in Indore commissioning in Q3 FY2027 and a 100-bed hospital in Malad, Mumbai.

Strategic Outlook & Management Commentary of Rainbow Children's Medicare (Q1 FY2027 Concall)

Management guidance outlines strategic priorities centered on network bed additions, regional cluster expansion, and margin protection.

  • Management targets scaling total bed capacity to 5,000 beds over the next 5 years via organic and selective inorganic additions.
  • Operating EBITDA margins are guided to sustain within the 28.0%–31.0% corridor through operating leverage at mature units.
  • Regional expansion will focus on strengthening footprints across Western India (Mumbai, Pune, Indore) and North-East India.
  • Mature hospital units are projected to sustain occupancy levels above 60% as patient volumes normalize.
  • Capital allocation strategy will prioritize funding brownfield and greenfield expansions via internal cash flows while maintaining a net cash balance sheet.

Management anticipates rising demand for specialized pediatric tertiary care and perinatal medicine to support patient volume execution. Operational focus centers on commissioning the Indore hospital in Q3 FY27, ramping up new regional units, and maintaining zero-debt balance sheet strength.

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.

Sources & References

  1. Rainbow Children's Medicare Q1 FY2027 Earnings Conference Call Transcript (July 31, 2026 / August 04, 2026)
  2. Rainbow Children's Medicare Q1 FY2027 Unaudited Financial Results & Press Release Disclosures (July 29–30, 2026)
  3. Rainbow Children's Medicare Q4 & Full Year FY2026 Consolidated Financial Disclosures (May 2026)
  4. BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Rainbow Children's Medicare
  5. Ticker Finology Rainbow Children's Medicare Page 

Disclaimer
The information presented above on Rainbow Children's Medicare has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Rainbow Children's Medicare page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Read More
X